OTCM
USAQ
Market cap2mUSD
Jul 18, Last price
0.20USD
1D
0.00%
1Q
17.79%
IPO
-33.33%
Name
QHSLab Inc
Chart & Performance
P/E
—
P/S
1.06
EPS
—
Div Yield, %
—
Shrs. gr., 5y
13.72%
Rev. gr., 5y
%
Revenues
2m
+51.31%
Net income
-259k
L-44.65%
CFO
142k
P
Profile
QHSLab, Inc., a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It also develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine. In addition, the company provides quality health score lab expert system (QHSLab), a cloud-based SaaS system, which provides physicians and healthcare organizations with the ability to capture and store patient information electronically in a secure database; and distributes AllergiEnd, a diagnostic related product and allergen immunotherapy treatments to primary care physicians. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. QHSLab, Inc. has a strategic alliance with Medical License Factory, LLC. The company was incorporated in 1983 and is based in West Palm Beach, Florida.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | 2,132 51.31% | 1,409 13.34% | 1,243 -12.11% | |||||||
Cost of revenue | 1,854 | 1,577 | 1,732 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 278 | (168) | (488) | |||||||
NOPBT Margin | 13.03% | |||||||||
Operating Taxes | 435 | |||||||||
Tax Rate | ||||||||||
NOPAT | 278 | (168) | (924) | |||||||
Net income | (259) -44.65% | (468) -67.28% | (1,431) 40.80% | |||||||
Dividends | (89) | |||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 50 | |||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | 1,722 | 1,782 | 1,504 | |||||||
Long-term debt | 174 | |||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | 1,565 | 1,730 | 1,500 | |||||||
| Cash flow | ||||||||||
Cash from operating activities | 142 | (160) | (351) | |||||||
CAPEX | (3) | (37) | ||||||||
Cash from investing activities | (37) | |||||||||
Cash from financing activities | (37) | 33 | 280 | |||||||
FCF | 423 | (49) | (844) | |||||||
| Balance | ||||||||||
Cash | 157 | 52 | 179 | |||||||
Long term investments | ||||||||||
Excess cash | 51 | 117 | ||||||||
Stockholders' equity | (4,330) | (3,982) | (3,514) | |||||||
Invested Capital | 5,445 | 5,388 | 5,269 | |||||||
ROIC | 5.13% | |||||||||
ROCE | 24.93% | |||||||||
| EV | ||||||||||
Common stock shares outstanding | 10,288 | 9,417 | 8,997 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | 424 | (21) | (360) | |||||||
EV/EBITDA | ||||||||||
Interest | 465 | 230 | 433 | |||||||
Interest/NOPBT | 167.38% | |||||||||